The immunodominant conserved epitopes B7/N105- and B44/N322-specific CD8+ T cells have been generated from COVID-19 convalescents and utilized to develop adoptive immunotherapy, exhibited robust functional capacity and cytotoxic potential against different virus variants, which may have important clinical value for immunocompromised patients with lethal infectious complications (39). This evidence concerns the gene CD8A and COVID-19.